Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>RBI has expanded PSL norms higher loan limits, broader beneficiary definitions, and new incentives to push credit into underserved sectors and geographies.</li>
<li>This modernizes India's financial inclusion framework, aligns credit policy with inflation, green goals, and gender inclusion, and reduces compliance friction for banks.</li>
<li>PSL is evolving into a growth lever, not just a mandate impacting loan strategies, certificate pricing, and long-term retail credit profitability for banks and fintechs.</li>
</ul>


RBI has expanded PSL norms higher loan limits, broader beneficiary definitions, and new incentives to push credit into underserved sectors and geographies.
This modernizes India's financial inclusion framework, aligns credit policy with inflation, green goals, and gender inclusion, and reduces compliance friction for banks.
PSL is evolving into a growth lever, not just a mandate impacting loan strategies, certificate pricing, and long-term retail credit profitability for banks and fintechs.


RBI’s Overhaul of India’s Priority Sector Lending Norms

<ul>
<li>Automobile industry is expected to witness a mixed performance in FY25 Volume growth, with robust growth in tractors, moderate increases in 2W’s and PV’s, and a slight decline in CV’s</li>
<li>Favorable farmer sentiment driving tractor demand and substantial export opportunities for 2W’s are key growth triggers anticipated.</li>
<li>
<a href="https://www.smartkarma.com/entities/escorts-kubota-ltd" target="_blank" data-smartkarma-citation="entities:6773:1" rel="noopener">Escorts Kubota Limited (ESCORTS IN)</a> with a revenue share of 80% from tractor business, foresees significant growth driven by a robust domestic market and double-digit growth in their export business. </li>
</ul>


Automobile industry is expected to witness a mixed performance in FY25 Volume growth, with robust growth in tractors, moderate increases in 2W’s and PV’s, and a slight decline in CV’s
Favorable farmer sentiment driving tractor demand and substantial export opportunities for 2W’s are key growth triggers anticipated.

Escorts Kubota Limited (ESCORTS IN) with a revenue share of 80% from tractor business, foresees significant growth driven by a robust domestic market and double-digit growth in their export business. 


Automobile Industry FY25: Expectations for Different Verticals

External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

External broker reports(aggregated public sources)

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Brightstar Resources Limited is a gold exploration company based in Australia. The Company is focused on the Brightstar Project, a gold exploration property in Western Australia.

<ul><li>BTR has continued to advance its multi-mine strategy, with the first gold pour at Second Fortune announced this week.</li><li>The gold produced will contribute to funding the near-term development at Fish UG and Lord Byron OP, and long-term growth at Sandstone through exploration and studies.</li><li>Processing has commenced at Genesis Minerals’ (GMD) Laverton Mill under the agreed Ore Purchasing Agreement (OPA), marking a significant milestone in the CY25 production ramp up plan. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

BTR has continued to advance its multi-mine strategy, with the first gold pour at Second Fortune announced this week.The gold produced will contribute to funding the near-term development at Fish UG and Lord Byron OP, and long-term growth at Sandstone through exploration and studies.Processing has commenced at Genesis Minerals’ (GMD) Laverton Mill under the agreed Ore Purchasing Agreement (OPA), marking a significant milestone in the CY25 production ramp up plan. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Brightstar Resources (BTR) - Near Term Production Supporting Long Term Growth

External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Opthea Limited is a biologics drug developer for ophthalmic diseases. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.

<div><div><div><div><ul><li>OPT released Phase III data from its COAST study in wet AMD, assessing OPT-302 in combination with Eylea (standard of care) vs Eylea monotherapy.</li><li>The study failed to meet its primary endpoint, with the treatment arm underperforming standard of care.</li><li>This was a catastrophic negative surprise to us - the Phase II data in a relatively large patient cohort was statistically significant and compelling from a clinical relevance perspective. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

OPT released Phase III data from its COAST study in wet AMD, assessing OPT-302 in combination with Eylea (standard of care) vs Eylea monotherapy.The study failed to meet its primary endpoint, with the treatment arm underperforming standard of care.This was a catastrophic negative surprise to us - the Phase II data in a relatively large patient cohort was statistically significant and compelling from a clinical relevance perspective. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Opthea Limited - Blindsided: COAST Phase III Flop

Clover Corporation Limited produces and refines natural oils along with the sale and distribution of chemicals and related products to the pharmaceutical industry. The Company also researches, develops, and supplies DHA products.

<ul><li>Expansion into New Products: In its 1H25 update, management highlighted the growth of its new product segment, which now accounts for 50% of CLV’s revenue.</li><li>These products typically offer higher margins than the company’s traditional infant formula tuna oil DHA.</li><li>Notable new offerings include Gelphorm which is used for UHT milks and other powers for seniors and toddlers milk – this product is unique to CLV and enhances profitability. We expect this segment to continue expanding.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Expansion into New Products: In its 1H25 update, management highlighted the growth of its new product segment, which now accounts for 50% of CLV’s revenue.These products typically offer higher margins than the company’s traditional infant formula tuna oil DHA.Notable new offerings include Gelphorm which is used for UHT milks and other powers for seniors and toddlers milk – this product is unique to CLV and enhances profitability. We expect this segment to continue expanding.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clover Corporation Limited (CLV) - 1H25 Results – Turnaround Underway

Australia
Insights on Australia

RBI’s Overhaul of India’s Priority Sector Lending Norms

RBI's expanded PSL norms aim to boost credit in underserved sectors, align with inflation and green goals, and reduce compliance friction for...

Nimish Maheshwari

Automobile Industry FY25: Expectations for Different Verticals

Mixed performance expected in FY25 for automobile industry with strong growth in tractors, moderate increases in 2W’s and PV’s, and slight decline...

Nimish Maheshwari

Brightstar Resources (BTR) - Near Term Production Supporting Long Term Growth

Coupling this with the now producing Second Fortune mine, BTR is generating positive free cash flow whilst remaining debt and hedge-free.

Taylor Collison

Opthea Limited - Blindsided: COAST Phase III Flop

OPT released Phase III data from its COAST study in wet AMD, assessing OPT-302 in combination with Eylea (standard of care) vs Eylea monotherapy.

Canaccord Genuity

Clover Corporation Limited (CLV) - 1H25 Results – Turnaround Underway

Expansion into New Products: In its 1H25 update, management highlighted the growth of its new product segment, which now accounts for 50% of CLV’s...

Taylor Collison

RBI’s Overhaul of India’s Priority Sector Lending Norms

​RBI's expanded PSL norms aim to boost credit in underserved sectors, align with inflation and green goals, and reduce compliance friction for...

Nimish Maheshwari

Automobile Industry FY25: Expectations for Different Verticals

​Mixed performance expected in FY25 for automobile industry with strong growth in tractors, moderate increases in 2W’s and PV’s, and slight decline...

Nimish Maheshwari

Brightstar Resources (BTR) - Near Term Production Supporting Long Term Growth

Coupling this with the now producing Second Fortune mine, BTR is generating positive free cash flow whilst remaining debt and hedge-free.

Taylor Collison

Opthea Limited - Blindsided: COAST Phase III Flop

OPT released Phase III data from its COAST study in wet AMD, assessing OPT-302 in combination with Eylea (standard of care) vs Eylea monotherapy.

Canaccord Genuity

Clover Corporation Limited (CLV) - 1H25 Results – Turnaround Underway

Expansion into New Products: In its 1H25 update, management highlighted the growth of its new product segment, which now accounts for 50% of CLV’s...

Taylor Collison

RBI's expanded PSL norms aim to boost credit in underserved sectors, align with inflation and green goals, and reduce compliance friction for...

Mixed performance expected in FY25 for automobile industry with strong growth in tractors, moderate increases in 2W’s and PV’s, and slight decline...